Cargando…

Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management

The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). At present, the COVID-19 has been prevalent worldwide for more than a year and caused more than four million deaths. Liver injury was frequently observed in patients with COVID...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Yanlan, Yang, Xinyu, Bian, Hua, Xia, Mingfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487451/ https://www.ncbi.nlm.nih.gov/pubmed/34602072 http://dx.doi.org/10.1186/s12944-021-01564-z

Ejemplares similares

Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight
por: Vasques-Monteiro, Isabela Macedo Lopes, et al.
Publicado: (2021)

Interaction of metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease with advanced fibrosis in the death and intubation of patients hospitalized with coronavirus disease 2019
por: Vázquez‐Medina, Martín Uriel, et al.
Publicado: (2022)

Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019
por: Gao, Feng, et al.
Publicado: (2021)

Update on genetics and epigenetics in metabolic associated fatty liver disease
por: Zhu, Xiaopeng, et al.
Publicado: (2022)

A novel model for detecting advanced fibrosis in patients with nonalcoholic fatty liver disease
por: Yang, Xinyu, et al.
Publicado: (2022)

Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease
por: Yang, Xinyu, et al.
Publicado: (2021)

Coronavirus disease 2019 and non-alcoholic fatty liver disease
por: Bellanti, Francesco, et al.
Publicado: (2021)

Association of metabolic‐associated fatty liver disease and risk of severe coronavirus disease 2019 illness
por: Sy‐Janairo, Marianne Linley, et al.
Publicado: (2020)

The Impact of Nonalcoholic Fatty Liver Disease on the Outcomes of Coronavirus Disease 2019 Infection
por: Asemota, Joseph, et al.
Publicado: (2022)

Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
por: Prasoppokakorn, Thaninee, et al.
Publicado: (2021)

A Bidirectional Relationship Between Hyperuricemia and Metabolic Dysfunction-Associated Fatty Liver Disease
por: Yang, Chengzhang, et al.
Publicado: (2022)

The relationship between skeletal muscle mass to visceral fat area ratio and metabolic dysfunction-associated fatty liver disease subtypes in middle-aged and elderly population: a single-center retrospective study
por: Xing, Mengchen, et al.
Publicado: (2023)

Mechanism and treatment of olfactory dysfunction caused by coronavirus disease 2019
por: Hu, Bian, et al.
Publicado: (2023)

Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease
por: Chang, Xinxia, et al.
Publicado: (2016)

Aerobic Exercise in the Management of Metabolic Dysfunction Associated Fatty Liver Disease
por: Machado, Mariana Verdelho
Publicado: (2021)

Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
por: Alam, Shahinul, et al.
Publicado: (2021)

Relationship between Adipokines and Cardiovascular Ultrasound Parameters in Metabolic-Dysfunction-Associated Fatty Liver Disease
por: Ismaiel, Abdulrahman, et al.
Publicado: (2021)

The nonlinear relationship between thyroid function parameters and metabolic dysfunction-associated fatty liver disease
por: Hu, Yingying, et al.
Publicado: (2023)

The relationship between metabolic dysfunction-associated fatty liver disease and the incidence rate of extrahepatic cancer
por: Wei, Suosu, et al.
Publicado: (2023)

Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
por: Han, A Lum
Publicado: (2022)

Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update
por: Alharthi, Jawaher, et al.
Publicado: (2022)

Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions
por: Lee, Jung Il
Publicado: (2022)

Therapeutic developments in metabolic dysfunction-associated fatty liver disease
por: Shi, Yiwen, et al.
Publicado: (2022)

Cardiometabolic characterization in metabolic dysfunction–associated fatty liver disease
por: Perdomo, Carolina M., et al.
Publicado: (2022)

Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
por: Zhou, Xiao-Dong, et al.
Publicado: (2022)

CT-based methods for assessment of metabolic dysfunction associated with fatty liver disease
por: Hu, Na, et al.
Publicado: (2023)

Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function than Nonalcoholic Fatty Liver Disease
por: Miao, Lei, et al.
Publicado: (2022)

Association between non-alcoholic fatty liver disease-associated hepatic fibrosis and bone mineral density in postmenopausal women with type 2 diabetes or impaired glucose regulation
por: Zhu, Xiaopeng, et al.
Publicado: (2020)

Association between Metabolic Dysfunction-associated Fatty Liver Disease and Cognitive Impairment
por: Yu, Qiang, et al.
Publicado: (2022)

The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease
por: Martín-Mateos, Rosa, et al.
Publicado: (2021)

Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease
por: Jung, Han Na, et al.
Publicado: (2023)

Metabolic-associated Fatty Liver Disease
por: Zheng, Ming-Hua
Publicado: (2021)

Coronavirus Disease-2019 and Implications on the Liver
por: Campbell, Patrick T., et al.
Publicado: (2023)

Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome
por: Abenavoli, Ludovico, et al.
Publicado: (2023)

Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment
por: Ding, Yuping, et al.
Publicado: (2023)

Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism
por: Yan, Hongmei, et al.
Publicado: (2021)

Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis
por: Wang, Xiaolin, et al.
Publicado: (2022)

Quality of Life in Adults with Metabolic Dysfunction-Associated Fatty Liver Disease
por: Hwang, Tae-In, et al.
Publicado: (2021)

Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease
por: Lin, Huapeng, et al.
Publicado: (2021)

Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)
por: Subramanian, Pallavi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mpa3jt8kkf7s929gvdaae4mkic